| Title: |
Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia [Cost-utility of dalbavancin in patients with non-severe ABSSSI in Italy] |
| Authors: |
Marcellusi, Andrea; Bini, Chiara; Rotundo, Maria Assunta; Cultrera, Rosario; Mennini, Francesco Saverio |
| Contributors: |
Marcellusi, Andrea; Bini, Chiara; Rotundo, Maria Assunta; Cultrera, Rosario; Mennini, Francesco Saverio |
| Publication Year: |
2020 |
| Collection: |
Università degli Studi di Ferrara: CINECA IRIS |
| Subject Terms: |
Cost-effectiveness analysis; Cost-utility analysis; Dalbavancin; Staphylococcal skin diseases |
| Description: |
Introduction: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibiotic therapies for the management of non-severe ABSSSIs from the National Health Service (NHS) perspective. Methods: A probabilistic decision tree model was developed considering a 30-days follow-up to simulate the therapeutic pathway of a patient treated with dalbavancin or Standard of Care (SoC). The model considered three mutually exclusive health states: a) discharge of patients from the emergency department, b) discharge of patients after one night from admission, c) discharge after 24 or 36 hours from admission. A one-way deterministic sensitivity analysis and a probabilistic sensitivity analysis were conducted. Results: The analysis showed that the use of dalbavancin in patients with non-severe ABSSSI compared to SoC could generate a reduction in costs (– € 291.6 per patient treated) and an increase in QALYs (+0.0018 per patient treated). In 99.7% of the simulations carried out, dalbavancin was dominant compared to the SoC. Considering a threshold for the willingness to pay of € 30,000 for QALY gained, the minimum level of efficacy of dalbavancin so that the treatment can be considered cost-effective compared to the SoC was equal to 69.4%. Conclusions: The analysis showed that dalbavancin may represent a cost-effective option compared to SoC for the treatment of patients with non-severe ABSSSI. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
Italian |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/WOS:000592504500001; volume:7; issue:1; firstpage:92; lastpage:100; numberofpages:9; journal:GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT; https://hdl.handle.net/11392/2433766; https://journals.aboutscience.eu/index.php/grhta/article/view/2138/2159; https://journals.aboutscience.eu/index.php/grhta/article/view/2138 |
| DOI: |
10.33393/grhta.2020.2138 |
| Availability: |
https://hdl.handle.net/11392/2433766; https://doi.org/10.33393/grhta.2020.2138; https://journals.aboutscience.eu/index.php/grhta/article/view/2138/2159; https://journals.aboutscience.eu/index.php/grhta/article/view/2138 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc/4.0/ |
| Accession Number: |
edsbas.C9FF9631 |
| Database: |
BASE |